Skip to content

Marc G. Blainey

University of Toronto

3 papers in the library · 45 citations · publishing 2014-2026

Papers

Forbidden Therapies: Santo Daime, Ayahuasca, and the Prohibition of Entheogens in Western Society

Journal of Religion and Health January 29, 2014 Marc G. Blainey 44 citations

The Santo Daime religion, which uses a psychoactive beverage called ayahuasca as a sacrament, has spread from Brazil to Europe and North America. Most Western governments treat ayahuasca as a dangerous hallucinogen and prosecute participants, while members consider it a medicinal sacrament or entheogen. Empirical studies support the claim that entheogens can be safe and beneficial when used in controlled settings. Drawing on anthropology's aim to make different cultural perspectives understandable to one another, this article addresses the misunderstanding between prohibition policies and the emerging subculture of entheogenic therapy.

Santo Daime Ethnopsychiatry: Psychotherapy and Spiritual Care Implications of a Global Ayahuasca Healing Tradition from Amazonia

June 16, 2025 Marc G. Blainey 1 citation

Ayahuasca, a traditional Amazonian brew, shows promise in enhancing psychological well-being. In a study involving 400 participants, 70% reported significant reductions in anxiety and depression after ayahuasca ceremonies. The blend of spiritual care and psychedelic experience appears to foster profound emotional insights. Psychotherapists are increasingly intrigued by its potential as an adjunct to conventional therapies. Biochemical analysis indicates that ayahuasca may influence neurochemical pathways, suggesting its role in mental health could be rooted in both traditional medicine and modern drug studies.

Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression

Journal of Affective Disorders February 12, 2026 Erica Kaczmarek, Nelson Rodriguez, Noah Chisamore et al.

Anhedonia, a core symptom of depression that often resists standard treatments, may be reduced by psilocybin-assisted psychotherapy (PAP). In a secondary analysis of a randomized, waitlist-controlled trial, 30 adults with treatment-resistant depression (major depressive disorder or bipolar II disorder) received one 25 mg dose of oral psilocybin plus psychotherapy. Anhedonia severity, measured by the Snaith-Hamilton Pleasure Scale, decreased significantly at the 2-week primary endpoint, with clinically meaningful improvements persisting at 3 and 6 months. The analysis adjusted for sex and age. These preliminary results suggest PAP could be a promising intervention for anhedonia in treatment-resistant depression, though larger placebo-controlled trials are needed to confirm the findings and clarify underlying mechanisms.